A Bayesian Network Model of Proteins' Association with Promyelocytic Leukemia (PML) Nuclear Bodies

被引:5
|
作者
Boden, Mikael [1 ]
Dellaire, Graham [2 ]
Burrage, Kevin [1 ,3 ]
Bailey, Timothy L. [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia
[2] Dalhousie Univ, Fac Med, Dept Pathol, Halifax, NS, Canada
[3] Univ Oxford, Oxford Ctr Integrat Syst Biol, Oxford, England
关键词
cancer genomics; functional genomics; proteins; sequences; LOCALIZATION; DATABASE;
D O I
10.1089/cmb.2009.0140
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The modularity that nuclear organization brings has the potential to explain the function of aggregates of proteins and RNA. Promyelocytic leukemia nuclear bodies are implicated in important regulatory processes. To understand the complement of proteins associated with these intra-nuclear bodies, we construct a Bayesian network model that integrates sequence and protein-protein interaction data. The model predicts association with promyelocytic leukemia nuclear bodies accurately when interaction data is available. At a false positive rate of 10%, the true positive rate is almost 50%, indicated by an independent nuclear proteome reference set. The model provides strong support for further expanding the protein complement with several important regulators and a richer functional repertoire. Using special support vector machine (SVM)-nodes (equipped with string kernels), the Bayesian network is also able to produce predictions on the basis of sequence only, with an accuracy superior to that of baseline models. Supplementary Material is available online at www.liebertonline.com.
引用
收藏
页码:617 / 630
页数:14
相关论文
共 50 条
  • [1] Pondering the promyelocytic leukemia protein (PML) puzzle: Possible functions for PML nuclear bodies
    Borden, KLB
    MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (15) : 5259 - 5269
  • [2] Targeting Promyelocytic Leukemia Protein: A Means to Regulating PML Nuclear Bodies
    Reineke, Erin L.
    Kao, Hung-Ying
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2009, 5 (04): : 366 - 376
  • [3] Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies
    Hirano, Seishiro
    Udagawa, Osamu
    PLOS ONE, 2022, 17 (05):
  • [4] Acute promyelocytic leukemia, arsenic, and PML bodies
    de The, Hugues
    Le Bras, Morgane
    Lallemand-Breitenbach, Valerie
    JOURNAL OF CELL BIOLOGY, 2012, 198 (01): : 11 - 21
  • [5] Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA
    Boisvert, FM
    Hendzel, MJ
    Bazett-Jones, DP
    JOURNAL OF CELL BIOLOGY, 2000, 148 (02): : 283 - 292
  • [6] The acute promyelocytic leukemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies.
    Ruthardt, M
    Orleth, A
    Tomassoni, L
    Puccetti, E
    Riganelli, D
    Alcalay, M
    Mannucci, R
    Nicoletti, I
    Grignani, F
    Fagioli, M
    Hoelzer, D
    Pelicci, PG
    BLOOD, 1997, 90 (10) : 1437 - 1437
  • [7] Nucleoli and Promyelocytic Leukemia Protein (PML) bodies are phase separated nuclear protein quality control compartments for misfolded proteins
    Mediani, L.
    Guillen-Boixet, J.
    Alberti, S.
    Carra, S.
    MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (06)
  • [8] PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?
    Brown, Nicola J. M.
    Ramalho, Michal
    Pedersen, Eva W.
    Moravcsik, Eva
    Solomon, Ellen
    Grimwade, David
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2009, 14 : 1684 - 1707
  • [9] Overexpression of promyelocytic leukemia protein and alteration of PML nuclear bodies in early stage of hepatocarcinogenesis
    Yoon, GS
    Yu, E
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2001, 16 (04) : 433 - 438
  • [10] Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B
    Wang, Chao
    Su, Li De
    Shao, Yi Ming
    Chen, Wei Zhong
    Bu, Na
    Hao, Rui
    Ma, Li Ya
    Hussain, Liaqat
    Lu, Xiao Yang
    Wang, Qian Qian
    Naranmandura, Hua
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 384